Y-mAbs Therapeutics, Inc. (YMAB) Social Stream



Y-mAbs Therapeutics, Inc. (YMAB): $10.22

-0.77 (-7.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Y-mAbs Therapeutics Inc (YMAB) Price Targets From Analysts

Use the tables below to see what analysts covering Y-mAbs Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-06 6 $68 $25 $43.4 $10.99 294.9%
2021-11-09 6 $68 $39 $54.4 $10.99 395%
2021-11-16 6 $68 $30 $49 $10.99 345.86%
2021-12-22 6 $68 $25 $46.2 $10.99 320.38%
2022-01-03 6 $68 $25 $45.6 $10.99 314.92%

The Trend in the Analyst Price Target


Over the past 152 days, YMAB's average price target has gone down $12.46.

Over the past 50 weeks, YMAB's average upside potential has been 87.42%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-25 6 70 45 57.75 27.35 111.15%
2021-07-24 10 68 45 57.00 35.33 61.34%
2021-02-27 5 67 45 58.78 35.17 67.13%
2021-12-22 6 68 25 46.20 17.13 169.7%
2021-03-06 5 70 45 59.33 32.64 81.77%

YMAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.67 4 0 2 0 0 6

The Trend in the Broker Recommendations


YMAB's average broker recommendation rating worsened by 0.42 over the prior 17 months.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for YMAB as an investment opportunity.

  • In terms of how Y-mAbs Therapeutics Inc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 469.44% of that group.
  • In terms of how Y-mAbs Therapeutics Inc fares relative to all US stocks, note that its variance in analysts' estimates is lower than -339.25% of that group.
  • In the context of Pharmaceutical Products stocks, Y-mAbs Therapeutics Inc's average analyst price target is greater than 335.49% of them.
  • Y-mAbs Therapeutics Inc's number of analysts covering the stock is greater than 188.45% of stocks in the mid market cap category.

Stocks similar to Y-mAbs Therapeutics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are XNCR, VERV, and UTHR.

What is the outlook for YMAB? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.622 seconds.